The mean overall survival time of colon cancer patients with high HOXB-AS3 peptide expression was 1.6 times that of those with low HOXB-AS3 peptide expression, suggesting that high HOXB-AS3 peptide expression may reduce the risk of death. Here, PDS5B is linked to malignant colon neoplasm.